Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Concert Pharmaceuticals

Concert Pharmaceuticals
2006 FOUNDED
PUBLIC STATUS
71-80 EMPLOYEES
CNCE STOCK SYMBOL
$5.88 SHARE PRICE (As of Friday Closing)
Description

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 99 Hayden Avenue
  • Suite 500
  • Lexington, MA 02421
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Concert Pharmaceuticals’s full profile, request a free trial.

Concert Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$5.36 - $17.83 $140M $5.86 -$3.34 210K 23.8M

Concert Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 143,249 116,427 382,015 121,210
Revenue 1,078 10,505 143,891 174
EBITDA (77,110) (54,464) 97,162 (49,827)
Net Income (78,730) (56,024) 95,639 (50,720)
Total Assets 166,601 192,547 211,736 100,395
Total Debt 16,579
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Concert Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Concert Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Concert Pharmaceuticals Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cortexyme Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
0 000000000000 Venture Capital-Backed Salt Lake City, UT 000.00 00000 00000 000.00
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
0000000 Venture Capital-Backed Singapore, Singapore 00 00000 0000000000 0 00000
To view this company’s complete list of competitors, request access »

Concert Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Concert Pharmaceuticals Executive Team (7)

Name Title Board
Seat
Contact
Info
Roger Tung Ph.D Chief Executive Officer & Founder
Marc Becker Chief Financial Officer
Nancy Stuart Chief Operating Officer
Jeff Munsie JD Chief Legal Officer
James Cassella Ph.D Executive

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Concert Pharmaceuticals Board Members (12)

Name Representing Role Since Contact
Info
Christi van Heek Concert Pharmaceuticals Board Member 000 0000
Peter Hutt Self Board Member 000 0000
Richard Aldrich Self Chairman & Founder 000 0000
Ronald Barrett Ph.D Self Board Member 000 0000
Wendell Wierenga Ph.D Self Board Member 000 0000

6 Former Board Members

You’re viewing 5 of 12 board members. Get the full list »